2-Methyl-iPALT

2-Methyl-iPALT, or 2-methyl-ALiPT, also known as 2-methyl-N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3002, is a serotonin receptor modulator of the tryptamine family. It is the 2-methyl derivative of iPALT. The drug is very similar in structure to 2-methyl-DiPT, which Alexander Shulgin hypothesized would be a DiPT-like selective auditory hallucinogen but never synthesized nor tested.

Pharmacology

Pharmacodynamics

2-Methyl-iPALT is a non-selective serotonin receptor agonist, including of the serotonin 5-HT_1B, 5-HT_2A, 5-HT_2B, and 5-HT₆ receptors, but not of the serotonin 5-HT_1A receptor. However, it shows rather low, micromolar potency for most of these actions, with for example 264-fold lower potency as a serotonin 5-HT_2A receptor agonist than the known psychedelic drug 5-MeO-iPALT. The drug is inactive as a monoamine reuptake inhibitor.

Chemistry

Synthesis

The chemical synthesis of 2-methyl-iPALT has been described.

Analogues

s of 2-methyl-iPALT include 5-MeO-iPALT, 4-HO-iPALT, 2-methyl-DMT, 2-methyl-DET, and 2-methyl-DiPT, among others.

History

2-Methyl-iPALT was patented by the Alexander Shulgin Research Institute in 2024.